ResearchMoz presents professional and in-depth study of "Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017".
This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1497548
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman's external genitals, called the vulva.
The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.
Scope
Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
View Complete TOC with tables & Figures @ https://www.researchmoz.us/lower-female-reproductive-system-cancers-drug-development-pipeline-review-2017-report.html/toc
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Lower Female Reproductive System Cancers Report Coverage 8
2.2 Cervical Cancer – Overview 8
2.3 Vaginal Cancer – Overview 8
2.4 Vulvar Cancer – Overview 8
3 Therapeutics Development 9
3.1 Cervical Cancer 9
3.2 Vaginal Cancer 24
3.3 Vulvar Cancer 27
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1497548
4 Therapeutics Assessment 30
4.1 Cervical Cancer 30
4.2 Vaginal Cancer 42
4.3 Vulvar Cancer 48
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1497548
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman's external genitals, called the vulva.
The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.
Scope
Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?
Reasons to buy
Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
View Complete TOC with tables & Figures @ https://www.researchmoz.us/lower-female-reproductive-system-cancers-drug-development-pipeline-review-2017-report.html/toc
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Lower Female Reproductive System Cancers Report Coverage 8
2.2 Cervical Cancer – Overview 8
2.3 Vaginal Cancer – Overview 8
2.4 Vulvar Cancer – Overview 8
3 Therapeutics Development 9
3.1 Cervical Cancer 9
3.2 Vaginal Cancer 24
3.3 Vulvar Cancer 27
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1497548
4 Therapeutics Assessment 30
4.1 Cervical Cancer 30
4.2 Vaginal Cancer 42
4.3 Vulvar Cancer 48
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment